VLA1553
Phase 3Biologic
VLA1553 is one of 44 biologic programs targeting Immunodeficiency. It is currently in Phase 3.
2
Indications
6
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
296 competitors in Immunodeficiency
#DrugCompanyPhaseTrials
1Repatha
AmgenPhase 3
Farxiga
AstraZenecaPhase 3
Emtriva
GileadPhase 3
Edurant Ped
WWim Janssens
Phase 3
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Retrovir
BBp Consulting, Inc
Phase 3
Vemlidy
GileadPhase 3
Livalo
MMedicure
Phase 3
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Immunoglobulin
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chikungunya Virus2 trials
Immunodeficiency1 trial
Immunogenicity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VLA1553. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- VValneva Austria GmbH